High CD34 cell doses do not worsen regimen-related toxicity or early mortality after autologous blood stem cell transplantation for breast cancer

I. Braunschweig, N. Q. Mirza, G. Rondon, J. Lauppe, R. Mehra, J. Gajewski, M. Körbling, Y. O. Huh, D. Geisler, A. P. Gee, R. Champlin, D. Przepiorka

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: Some transplant-related complications, such as the engraftment syndrome, are thought to be mediated by cytokines released during expansion of hematopoietic progenitors at the time of neutrophil recovery. Since there is an inverse correlation between CD34+ cell dose and time to neutrophil recovery, we sought to determine if peritransplant toxicity and early mortality were adversely affected by high CD34+ cell doses. Methods: The study group included 186 women with breast cancer who received high-dose cyclophosphamide, carmustine, thiotepa and an autologous PBSC transplant. The median CD34+ cell dose was 5.9 X 106/kg (1.0-154.7 X 106/kg). Patients were categorized by CD34+ cell dose (1.0-3.5, 3.6-5.9, 6.0-19.9, and 20.0-154.7 X 106/kg) for assessment of outcomes. Results: Grades 2-4 mucositis occurred in 49%, cardiac toxicity in 7%, pulmonary toxicity in 5%, cystitis in 4%, diarrhea in 3%, renal toxicity in 1%, and central nervous system toxicity in 1%. A Grade 2-4 regimen-related toxicity occurred in 109 patients (59%) and Grade 3-4 in eight patients (4%). Overall survival was 100% at Day 30, 96% at Day 90, and 89% at 1 year. Treatment-related mortality was 3.8%. In multivariate analyses that included prior chemotherapy, disease status, visceral metastases, prior chest radiation and age, CD34+ cell dose group was not an independent risk factor for Grade 2-4 mucositis, Grade 2-4 maximum toxicity, Grade ≥3 cumulative toxicity, 90 day survival or 1 year survival. Discussion: We conclude that CD34+ cell doses >20 X 106/kg do not affect transplant outcome in a negative or positive fashion.

Original languageEnglish (US)
Pages (from-to)105-110
Number of pages6
JournalCytotherapy
Volume2
Issue number2
StatePublished - 2000
Externally publishedYes

Fingerprint

Stem Cell Transplantation
Blood Cells
Breast Neoplasms
Mortality
Mucositis
Survival
Neutrophils
Thiotepa
Transplants
Carmustine
Cystitis
Autografts
Cyclophosphamide
Diarrhea
Thorax
Multivariate Analysis
Central Nervous System
Outcome Assessment (Health Care)
Radiation
Cytokines

Keywords

  • Autologous transplantation
  • Breast cancer
  • CD34 cells
  • Peripheral blood stem cells
  • Toxicity

ASJC Scopus subject areas

  • Immunology

Cite this

Braunschweig, I., Mirza, N. Q., Rondon, G., Lauppe, J., Mehra, R., Gajewski, J., ... Przepiorka, D. (2000). High CD34 cell doses do not worsen regimen-related toxicity or early mortality after autologous blood stem cell transplantation for breast cancer. Cytotherapy, 2(2), 105-110.

High CD34 cell doses do not worsen regimen-related toxicity or early mortality after autologous blood stem cell transplantation for breast cancer. / Braunschweig, I.; Mirza, N. Q.; Rondon, G.; Lauppe, J.; Mehra, R.; Gajewski, J.; Körbling, M.; Huh, Y. O.; Geisler, D.; Gee, A. P.; Champlin, R.; Przepiorka, D.

In: Cytotherapy, Vol. 2, No. 2, 2000, p. 105-110.

Research output: Contribution to journalArticle

Braunschweig, I, Mirza, NQ, Rondon, G, Lauppe, J, Mehra, R, Gajewski, J, Körbling, M, Huh, YO, Geisler, D, Gee, AP, Champlin, R & Przepiorka, D 2000, 'High CD34 cell doses do not worsen regimen-related toxicity or early mortality after autologous blood stem cell transplantation for breast cancer', Cytotherapy, vol. 2, no. 2, pp. 105-110.
Braunschweig, I. ; Mirza, N. Q. ; Rondon, G. ; Lauppe, J. ; Mehra, R. ; Gajewski, J. ; Körbling, M. ; Huh, Y. O. ; Geisler, D. ; Gee, A. P. ; Champlin, R. ; Przepiorka, D. / High CD34 cell doses do not worsen regimen-related toxicity or early mortality after autologous blood stem cell transplantation for breast cancer. In: Cytotherapy. 2000 ; Vol. 2, No. 2. pp. 105-110.
@article{16929ac7777341eb9b82c18fdf63a582,
title = "High CD34 cell doses do not worsen regimen-related toxicity or early mortality after autologous blood stem cell transplantation for breast cancer",
abstract = "Background: Some transplant-related complications, such as the engraftment syndrome, are thought to be mediated by cytokines released during expansion of hematopoietic progenitors at the time of neutrophil recovery. Since there is an inverse correlation between CD34+ cell dose and time to neutrophil recovery, we sought to determine if peritransplant toxicity and early mortality were adversely affected by high CD34+ cell doses. Methods: The study group included 186 women with breast cancer who received high-dose cyclophosphamide, carmustine, thiotepa and an autologous PBSC transplant. The median CD34+ cell dose was 5.9 X 106/kg (1.0-154.7 X 106/kg). Patients were categorized by CD34+ cell dose (1.0-3.5, 3.6-5.9, 6.0-19.9, and 20.0-154.7 X 106/kg) for assessment of outcomes. Results: Grades 2-4 mucositis occurred in 49{\%}, cardiac toxicity in 7{\%}, pulmonary toxicity in 5{\%}, cystitis in 4{\%}, diarrhea in 3{\%}, renal toxicity in 1{\%}, and central nervous system toxicity in 1{\%}. A Grade 2-4 regimen-related toxicity occurred in 109 patients (59{\%}) and Grade 3-4 in eight patients (4{\%}). Overall survival was 100{\%} at Day 30, 96{\%} at Day 90, and 89{\%} at 1 year. Treatment-related mortality was 3.8{\%}. In multivariate analyses that included prior chemotherapy, disease status, visceral metastases, prior chest radiation and age, CD34+ cell dose group was not an independent risk factor for Grade 2-4 mucositis, Grade 2-4 maximum toxicity, Grade ≥3 cumulative toxicity, 90 day survival or 1 year survival. Discussion: We conclude that CD34+ cell doses >20 X 106/kg do not affect transplant outcome in a negative or positive fashion.",
keywords = "Autologous transplantation, Breast cancer, CD34 cells, Peripheral blood stem cells, Toxicity",
author = "I. Braunschweig and Mirza, {N. Q.} and G. Rondon and J. Lauppe and R. Mehra and J. Gajewski and M. K{\"o}rbling and Huh, {Y. O.} and D. Geisler and Gee, {A. P.} and R. Champlin and D. Przepiorka",
year = "2000",
language = "English (US)",
volume = "2",
pages = "105--110",
journal = "Cytotherapy",
issn = "1465-3249",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - High CD34 cell doses do not worsen regimen-related toxicity or early mortality after autologous blood stem cell transplantation for breast cancer

AU - Braunschweig, I.

AU - Mirza, N. Q.

AU - Rondon, G.

AU - Lauppe, J.

AU - Mehra, R.

AU - Gajewski, J.

AU - Körbling, M.

AU - Huh, Y. O.

AU - Geisler, D.

AU - Gee, A. P.

AU - Champlin, R.

AU - Przepiorka, D.

PY - 2000

Y1 - 2000

N2 - Background: Some transplant-related complications, such as the engraftment syndrome, are thought to be mediated by cytokines released during expansion of hematopoietic progenitors at the time of neutrophil recovery. Since there is an inverse correlation between CD34+ cell dose and time to neutrophil recovery, we sought to determine if peritransplant toxicity and early mortality were adversely affected by high CD34+ cell doses. Methods: The study group included 186 women with breast cancer who received high-dose cyclophosphamide, carmustine, thiotepa and an autologous PBSC transplant. The median CD34+ cell dose was 5.9 X 106/kg (1.0-154.7 X 106/kg). Patients were categorized by CD34+ cell dose (1.0-3.5, 3.6-5.9, 6.0-19.9, and 20.0-154.7 X 106/kg) for assessment of outcomes. Results: Grades 2-4 mucositis occurred in 49%, cardiac toxicity in 7%, pulmonary toxicity in 5%, cystitis in 4%, diarrhea in 3%, renal toxicity in 1%, and central nervous system toxicity in 1%. A Grade 2-4 regimen-related toxicity occurred in 109 patients (59%) and Grade 3-4 in eight patients (4%). Overall survival was 100% at Day 30, 96% at Day 90, and 89% at 1 year. Treatment-related mortality was 3.8%. In multivariate analyses that included prior chemotherapy, disease status, visceral metastases, prior chest radiation and age, CD34+ cell dose group was not an independent risk factor for Grade 2-4 mucositis, Grade 2-4 maximum toxicity, Grade ≥3 cumulative toxicity, 90 day survival or 1 year survival. Discussion: We conclude that CD34+ cell doses >20 X 106/kg do not affect transplant outcome in a negative or positive fashion.

AB - Background: Some transplant-related complications, such as the engraftment syndrome, are thought to be mediated by cytokines released during expansion of hematopoietic progenitors at the time of neutrophil recovery. Since there is an inverse correlation between CD34+ cell dose and time to neutrophil recovery, we sought to determine if peritransplant toxicity and early mortality were adversely affected by high CD34+ cell doses. Methods: The study group included 186 women with breast cancer who received high-dose cyclophosphamide, carmustine, thiotepa and an autologous PBSC transplant. The median CD34+ cell dose was 5.9 X 106/kg (1.0-154.7 X 106/kg). Patients were categorized by CD34+ cell dose (1.0-3.5, 3.6-5.9, 6.0-19.9, and 20.0-154.7 X 106/kg) for assessment of outcomes. Results: Grades 2-4 mucositis occurred in 49%, cardiac toxicity in 7%, pulmonary toxicity in 5%, cystitis in 4%, diarrhea in 3%, renal toxicity in 1%, and central nervous system toxicity in 1%. A Grade 2-4 regimen-related toxicity occurred in 109 patients (59%) and Grade 3-4 in eight patients (4%). Overall survival was 100% at Day 30, 96% at Day 90, and 89% at 1 year. Treatment-related mortality was 3.8%. In multivariate analyses that included prior chemotherapy, disease status, visceral metastases, prior chest radiation and age, CD34+ cell dose group was not an independent risk factor for Grade 2-4 mucositis, Grade 2-4 maximum toxicity, Grade ≥3 cumulative toxicity, 90 day survival or 1 year survival. Discussion: We conclude that CD34+ cell doses >20 X 106/kg do not affect transplant outcome in a negative or positive fashion.

KW - Autologous transplantation

KW - Breast cancer

KW - CD34 cells

KW - Peripheral blood stem cells

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=0033939059&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033939059&partnerID=8YFLogxK

M3 - Article

VL - 2

SP - 105

EP - 110

JO - Cytotherapy

JF - Cytotherapy

SN - 1465-3249

IS - 2

ER -